← Eichor
Study identifier: NCT05909059 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

CAR T-cell Therapy in Patients With Renal Dysfunction

Condition: Non-hodgkin Lymphoma,B Cell · Multiple Myeloma · Acute Lymphoblastic Leukemia, Adult  ·  Sponsor: Northside Hospital, Inc.

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Melhem Solh, MD  ·  404-255-1930  ·  msolh@bmtga.com

Caitlin Guzowski, MBA, MHA  ·  404-851-8523  ·  caitlin.guzowski@northside.com

Always discuss trial participation with your own doctor first.

Locations (1)

Caitlin GuzowskiAtlanta, Georgia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05909059